Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.52 |
| ▸ | CA1 | P00915 | 6/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.46 |
| ▸ | IAPP | P10997 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3066819 | 0.87 | TSHR (0.58) | — | |
| SCHEMBL3274537 | 0.85 | APP (0.68) | ALOX5OR51E2APPCYP19A1ALDH1A1 | |
| SCHEMBL3734531 | 0.84 | CYP4F2 (0.58) | CA2CA1APPGAAIAPP | |
| SCHEMBL14461366 | 0.84 | RAB9A (0.48) | ALDH1A1GAA | |
| SCHEMBL2003361 | 0.83 | ALDH1A1 (0.66) | CA2CA1ALDH1A1GAAGFER | |
| SCHEMBL23665899 | 0.83 | CYP3A4 (0.49) | ALOX5OR51E2ALDH1A1GAAGFER | |
| SCHEMBL26641492 | 0.83 | CDK8 (0.52) | CA2CA1ALOX5OR51E2ALDH1A1 | |
| SCHEMBL30643734 | 0.83 | CDK8 (0.52) | CA2CA1ALOX5OR51E2ALDH1A1 | |
| SCHEMBL18269500 | 0.82 | ALOX5 (0.53) | ALOX5OR51E2APPALDH1A1GAA | |
| SCHEMBL22209184 | 0.81 | CA2 (0.56) | CA2CA1ALOX5OR51E2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS LTD (GB) | 2023-11-09 | — | — | US | disclosed |
| EP-4214189-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL Business Ltd (GB) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022058733-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | UCL BUSINESS PLC (GB) | 2022-03-24 | — | — | WO | disclosed |
| CN-105848771-A | High-speed centrifugal mixing devices and methods of use | 迪美公司 | 2016-08-10 | — | — | CN | disclosed |
| EP-1559422-B1 | RECEPTOR FUNCTION CONTROLLING AGENT | TAKEDA PHARMACEUTICAL (JP) | 2014-04-30 | — | — | EP | disclosed |
| EP-2385032-A1 | GPR40 Receptor function regulator | Takeda Pharmaceutical Company Limited (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-8008525-B2 | For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-30 | — | — | US | disclosed |
| US-7960369-B2 | Receptor function regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-14 | — | — | US | disclosed |
| US-20090012093-A1 | Receptor Function Regulator | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20080167378-A1 | Receptor Function Regulation Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1688138-A1 | RECEPTOR FUNCTION REGULATING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2006-08-09 | — | — | EP | disclosed |
| EP-1559422-A1 | RECEPTOR FUNCTION CONTROLLING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-08-03 | — | — | EP | disclosed |
| US-4221919-A | Antiinflammatory substituted phenylacetic acids | SPOFA, UNITED PHARMACEUTICAL WORKS (CS) | 1980-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167378-A1 | Receptor Function Regulation Agent | GPR119, INSR, GPR88 | CA2 3522/4885CA1 4750/4885ALOX5 3007/4885 |
| US-20090012093-A1 | Receptor Function Regulator | GPR119, GIPR, INSR | CA2 1848/4885CA1 4525/4885ALOX5 3500/4885 |
| US-20230357134-A1 | AGENTS FOR USE IN THE TREATMENT OF AMYLOIDOSIS | TTR, C1R, APOB | CA2 1378/4885CA1 1417/4885ALOX5 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.